Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: Tuning of receptor selectivity and in vivo efficacy

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6376-6378

  Pippel, Marna ^a   Boyce, Kristen ^a   Venkatesan, Hariharan ^a   Phuong, Victor K ^a   Yan, Wen ^a   Barrett, Terrance D ^a   Lagaud, Guy ^a   Li, Lina ^a   Morton, Magda F ^a   Prendergast, Clodagh ^a   Wu, Xiaodong ^a   Shankley, Nigel P ^a   Rabinowitz, Michael H ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CCK receptor antagonist

Indexed keywords

AMYLASE; ANTHRANILIC ACID; ANTHRANILIC SULFOMANIDE; BENZOIC ACID DERIVATIVE; BENZOTHIAPYRAZOLE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; METHYL 2 AMINO 4,5 DICHLOROBENZOIC ACID; PENTAGASTRIN; QUINOXALINE; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; IN VIVO STUDY; NONHUMAN; PANCREAS SECRETION; RAT; STEADY STATE; STOMACH ACID; STOMACH ACID SECRETION; STOMACH EMPTYING;

AMINO ACID SUBSTITUTION; ANIMALS; ISOXAZOLES; MODELS, MOLECULAR; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; SIGNAL TRANSDUCTION; SULFONAMIDES; TREATMENT OUTCOME;

RATTUS;

EID: 71049164295     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.065     Document Type: Article

References (16)

1. Herranz R., Smith J.J., and Roe R.P. Med. Res. Rev. 23 (2003) 559
2. Berna M.J., Tapia J.A., Sancho V., and Jensen R.T. Curr. Opin. Pharmacol. 7 (2007) 583
3. Varnavas A., and Lassiani L. Expert Opin. Ther. Patents 16 (2006) 1193
4. Liddle R.A., Gertz B.J., Kanayama S., Beccaria L., Coker L.D., Turnbull T.A., and Morita E.T. J. Clin. Invest. 84 (1989) 1220
5. Kramer M.S., Cutler N.R., Ballenger J.C., Patterson W.M., Mendels J., Chenault A., Shrivastava R., Matzura-Wolfe D., Lines C., and Reines S. Biol. Psychiatry 37 (1995) 462
6. van Megen H.J.G.M., Westenberg H.G.M., den Boer1 J.A., Slaa1 B., van Es-Radhakishun F., and Pande A.C. Psychopharmacology 3 (1997) 243
7. Richter J.E. Best Pract. Res. Clin. Gastroenterol. 21 (2007) 609
8. Lehmann A. Eur. Rev. Med. Pharmacol. Sci. 12 (2008) 103
9. Tonini M., de Giorgio R., and de Ponti F. Drugs 64 (2004) 347
10. Scarpignato C., Pelosini I., and Di Mario F. Digest. Dis. 24 (2006) 11
11. Allison B.D., Phuong V.K., McAtee L.C., Rosen M., Morton M., Prendergast C., Barrett T., Lagaud G., Freedman J., Li L., Wu X., Venkatesan H., Pippel M., Woods C., Rizzolio M.C., Hack M., Hoey K., Deng X., King C., Shankley N.P., and Rabinowitz M.H. J. Med. Chem. 49 (2006) 6371
12. Pippel M., Allison B.D., Phuong V.K., Li L., Morton M.F., Prendergast C., Wu X., Shankley N.P., and Rabinowitz M.H. Bioorg. Med. Chem. Lett. 19 (2009) 6373
13. Koch P., Boelsterli J.J., Hirst D.R., and Walkinshaw M.D. J. Chem. Soc., Perkin Trans. 2 (1990) 1705
14. Barrett T.D., Yan W., Freedman J.M., Lagaud G.J., Breitenbucher J.G., and Shankley N.P. Br. J. Pharmacol. 153 (2008) 1650
15. Ghosh M.N., and Schild H.O. Br. J. Pharmacol. Chemother. 13 (1958) 54
16. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099